Literature DB >> 18575759

Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.

Florian Hohla1, Angelika Moder, Ursula Mayrhauser, Cornelia Hauser-Kronberger, Andrew V Schally, Jozsef L Varga, Marta Zarandi, Stefan Buchholz, Rudolf Huber, Elmar Aigner, Markus Ritter, Christian Datz.   

Abstract

Recent evidence indicates that growth hormone-releasing hormone (GHRH) functions as a growth factor for gastrointestinal (GI) tumours. The tumourigenic effects of GHRH appear to be mediated by the splice variant 1 (SV-1) of GHRH receptor as well as the full length pituitary type receptor for GHRH (GHRH-R). We examined the protein and mRNA expression of GHRH-R and SV-1 in normal human tissues and tumours of the gastrointestinal (GI-) tract by immunohistochemical staining and reverse transcriptase (RT)-PCR. Squamous cells and squamous cell carcinoma of the oesophagus were negative for GHRH-R and SV-1, while Barrett's mucosa and adenocarcinomas of the oesophagus showed a strong expression of both receptors. The expression of GHRH-R was absent in normal colonic mucosa other than neuroendocrine cells (NE) and lining epithelium (LE) but strong in tubular adenomas of the colon, while the staining for SV-1 was absent in cells other than NE. However, the expression of both receptors was significantly increased in tubulovillous adenomas and colorectal cancers. No differences were seen in protein levels for both receptors between normal and neoplastic tissues of the stomach, pancreas and liver. Because of low mRNA levels for both receptors in all samples tested, only a qualitative assessment could be made. However, mRNA for GHRH-R and SV-1 showed a near-perfect correlation with the assessment of receptor proteins by immunostaining. Our study shows that in contrast to normal mucosa, transformed mucosa of the oesophagus and the colon expresses GHRH-R and SV-1. This aberrant expression of GHRH-R and SV-1 in oesophageal and colorectal malignancies may provide a molecular target for a therapeutic approach based on GHRH antagonists.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575759

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer.

Authors:  Helena Pópulo; Bruno Nunes; Cristina Sampaio; Rui Batista; Marta Teixeira Pinto; Tiago B Gaspar; Leandro Miranda-Alves; Ren-Zhi Cai; Xian Yang Zhang; Andrew V Schally; Manuel Sobrinho-Simões; Paula Soares
Journal:  Horm Cancer       Date:  2017-09-18       Impact factor: 3.869

2.  GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.

Authors:  Ferenc G Rick; Stephan Seitz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Stefan Buchholz; Norman L Block; Florian Hohla
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

Review 3.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

Review 4.  Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.

Authors:  Florian Hohla; Thomas Winder; Richard Greil; Ferenc G Rick; Norman L Block; Andrew V Schally
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

5.  Filtrating colorectal cancer associated genes by integrated analyses of global DNA methylation and hydroxymethylation in cancer and normal tissue.

Authors:  Ming Li; Fei Gao; Yudong Xia; Yi Tang; Wei Zhao; Congcong Jin; Huijuan Luo; Junwen Wang; Qingshu Li; Yalan Wang
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

6.  Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.

Authors:  Xiao Xiong; Xiurong Ke; Lu Wang; Zhimeng Yao; Yi Guo; Xianyang Zhang; Yuping Chen; Chi Pui Pang; Andrew V Schally; Hao Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-10       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.